NICE set to block use of 'unaffordable' new breast cancer drug
A new breast cancer drug that can extend women’s lives by almost six months will not be recommended for routine NHS use, under draft guidance issued by the National Institute for Health and Care Excellence.
Get unlimited access
As a subscriber you will benefit from:
- Full online and mobile access to news and opinion stories
Customised email alerts straight to your inbox (over 30 alerts available)
- 4,500 practice articles in our archive
- Over £500 worth of CPD learning units